Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients

ABSTRACT: We evaluated blood samples from 6 patients with metastatic melanoma treated with anti-LAG3+anti-PD1 (160+480 mg) in a phase I trial (NCT01968109) using single-cell RNA and T cell receptor (TCR) sequencing (scRNA+TCRαβ-seq, 10X 5') combined with other multiomics profiling (flow, cytokine, TCRb-seq) from a larger cohort of 40 patients. This data set include three time points, including baseline, 1 month, and 3 month. The sorting is CD45+.

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER: Jani Huuhtanen 

PROVIDER: E-MTAB-12733 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress